1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve

 
• By Reed Miller

In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.

Core Valve In Situ
Medtronic's CoreValve transcatheter aortic valve in situ • Source: SOURCE: Medtronic PLC

Two-year results of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial show that transcatheter aortic valve replacement with Medtronic PLC's CoreValve or CoreValve Evolut R is noninferior to surgical valve replacement in patients with aortic stenosis at intermediate risk of complications during surgery.

"We made our two-year non-inferiority endpoint with very strong statistics," SURTAVI's lead investigator, surgeon Michael Reardon of Houston Methodist DeBakey...

More from Cardiology

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By Marion Webb

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 
• By Natasha Barrow

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

More from Device Area